INOVIQ (IIQ) Stock Price, News & Analysis

Company Overview

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$47.40 million
• P/E Ratio: N/A
• Dividend Yield: 15.56%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:IIQ
• CIK: N/A
• Web: www.inoviq.com
• Phone: 61 3 9548 7586
• Fax: N/A
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$6.55 million
• Net Margins: -1,224.84%
• Pretax Margin: N/A
• Return on Equity: -35.69%
• Return on Assets: -19.70%

Debt

• Debt-to-Equity Ratio: 2.02
• Current Ratio: 7.07
• Quick Ratio: 9.52

Sales & Book Value

• Annual Sales: A$1.56 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.22 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 111,530,000
• Free Float: N/A
• Market Cap: A$47.40 million
• Optionable: Not Optionable
• Beta: 2.04